Matinas BioPharma Holdings Inc
MTNB1.750USD
+0.020+1.16%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
8.90MMarket Cap
LossP/E TTM
More Details of Matinas BioPharma Holdings Inc Company
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.
Company Info
Ticker SymbolMTNB
Company nameMatinas BioPharma Holdings Inc
IPO dateJun 03, 2014
CEOMr. Jerome D. Jabbour, J.D.
Number of employees3
Security typeOrdinary Share
Fiscal year-endJun 03
AddressSuite 302
CityBEDMINSTER
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code07921
Phone19084431860
Websitehttps://www.matinasbiopharma.com/
Ticker SymbolMTNB
IPO dateJun 03, 2014
CEOMr. Jerome D. Jabbour, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lazar (David Elliot)
9.81%
Stern (Adam K.)
3.79%
Sanitam Partners LLC
3.79%
111 Equity Group LLC
3.31%
The Vanguard Group, Inc.
1.08%
Other
78.22%
Shareholders
Shareholders
Proportion
Lazar (David Elliot)
9.81%
Stern (Adam K.)
3.79%
Sanitam Partners LLC
3.79%
111 Equity Group LLC
3.31%
The Vanguard Group, Inc.
1.08%
Other
78.22%
Shareholder Types
Shareholders
Proportion
Individual Investor
13.83%
Corporation
7.10%
Investment Advisor
3.44%
Investment Advisor/Hedge Fund
1.28%
Hedge Fund
0.46%
Research Firm
0.02%
Other
73.87%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
92
935.12K
18.38%
-1.08M
2025Q1
95
951.53K
18.71%
-830.58K
2024Q4
93
476.15K
9.43%
-1.21M
2024Q3
96
1.46M
29.08%
+470.67K
2024Q2
100
917.39K
18.29%
+218.76K
2024Q1
105
652.02K
14.56%
-47.03K
2023Q4
117
656.55K
15.11%
-41.82K
2023Q3
118
657.56K
15.13%
-45.97K
2023Q2
125
652.59K
15.02%
-352.98K
2023Q1
136
706.75K
16.27%
-394.91K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Stern (Adam K.)
210.69K
4.14%
--
--
Apr 08, 2025
Sanitam Partners LLC
210.69K
4.14%
+210.69K
--
May 09, 2025
111 Equity Group LLC
183.64K
3.61%
-64.36K
-25.95%
Feb 13, 2025
The Vanguard Group, Inc.
59.73K
1.17%
-46.77K
-43.92%
Mar 31, 2025
Geode Capital Management, L.L.C.
46.74K
0.92%
+3.27K
+7.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
49.65K
0.98%
--
--
Mar 31, 2025
Sargent Investment Group, LLC
41.80K
0.82%
-22.40K
-34.89%
Mar 31, 2025
Renaissance Technologies LLC
22.37K
0.44%
+4.20K
+23.12%
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Date
Type
Ratio
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
Aug 20, 2024
Merger
50→1
